MS decreases the larger amplitude distribution in adult rats. by Jesús David Ayala-Rodríguez (17364296)

Patients with high baseline gut richness and diversity have significantly greater decreases in diversity over time. by Molly B. El Alam (10231830)

IRI group exhibited a significantly greater decrease in proportion of gambles accepted compared to the IRI group in the second block. by Yasuhiro Mochizuki (3308349)

DataSheet_1_Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

“…These effects were more significant than that of the PD-L1 inhibitor, BMS-8.…”

A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity. by Benedict J. Alter (9745466)

Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

SHG-44 did not lead to a significant production of ROS release. by Denis Mustafov (19137870)

As compared to HD, RRMS and T1D patients show significantly greater preponderance of rs2281808 CT/TT carriers. by Sushmita Sinha (348580)

County-level geographical septile distribution for the first 12 statistically significant factors with at least one statistically significant coefficient ranked by decreasing ΔIC. by Yanan Long (11784717)

Negative ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Positive ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Energy efficiency variation across cities in the Greater Bay Area. by YanFei Lei (19532983)

Subjects:

Boxplots for total calcium released to the citric acid, according to the solutions. by Thiago Saads Carvalho (14129325)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects: